Skip to main content
Top
Published in: Italian Journal of Pediatrics 1/2018

Open Access 01-12-2018 | Research

Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?

Authors: Claudia Santoro, Pia Bernardo, Antonietta Coppola, Umberto Pugliese, Mario Cirillo, Teresa Giugliano, Giulio Piluso, Giuseppe Cinalli, Salvatore Striano, Carmela Bravaccio, Silverio Perrotta

Published in: Italian Journal of Pediatrics | Issue 1/2018

Login to get access

Abstract

Background

Neurofibromatosis type 1 (NF1) is related to a generally increased prevalence of seizures. The mechanism underlying the increased predisposition to seizures has not been fully elucidated. The aim of the study was to evaluate the role of NF1 in seizures pathogenesis in a cohort of children with NF1 and seizures.

Methods

The medical records of 437 children (0–18 years old) with NF1 were reviewed. All children with at least one afebrile seizure were included. Demographic, clinical, neurological, NF1 mutation status, and EEG data were collected along with brain magnetic resonance imaging. Depending on etiology, structural seizures have been identified and were further classified as NF1 related or not.

Results

Nineteen patients (4.3%; 13 males) were included. NF1 was inherited in 7 (37.5%), with 3 maternal forms. Ten children with structural seizures were identified. Seven forms were identified someway related to NF1, two of which were associated to 17q11.2 microdeletion and hypoxic-ischemic encephalopathy. Any brain lesion that could explain seizures was found in nine patients, two third of these patients had a familiar history of epilepsy.

Conclusions

Our results suggest seizures are more frequent in NF1 children (4.3%) than in general pediatric population (0.3–0.5%) and that are someway related to NF1 in half of patients. Facing seizures in NF1, the clinician should first exclude brain tumors but also other, and rarer NF1-related scenarios, such as hydrocephalous and vasculopathies. Children with non-structural seizures frequently had a family history of epilepsy, raising questions about the pathogenic role of NF1. They should be approached as for the general population.
Literature
1.
go back to reference Arun D, Gutmann DH. Recent advances in neurofibromatosis type 1. Curr Opin Neurol. 2004;17:101–5.CrossRefPubMed Arun D, Gutmann DH. Recent advances in neurofibromatosis type 1. Curr Opin Neurol. 2004;17:101–5.CrossRefPubMed
2.
3.
go back to reference De Bella K, Poskitt K, Szudek J, Friedman JM. Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children. Neurology. 2000;54:1646–51.CrossRef De Bella K, Poskitt K, Szudek J, Friedman JM. Use of “unidentified bright objects” on MRI for diagnosis of neurofibromatosis 1 in children. Neurology. 2000;54:1646–51.CrossRef
4.
go back to reference Szudek J, Friedman JM. Unidentified bright objects associated with features of neurofibromatosis 1. Pediatr Neurol. 2002;27:123–7.CrossRefPubMed Szudek J, Friedman JM. Unidentified bright objects associated with features of neurofibromatosis 1. Pediatr Neurol. 2002;27:123–7.CrossRefPubMed
5.
go back to reference Gill DS, Hyman SL, Steinberg A, North KN. Age-related findings on MRI in neurofibromatosis type 1. Pediatr Radiol. 2006;36:1048–56.CrossRefPubMed Gill DS, Hyman SL, Steinberg A, North KN. Age-related findings on MRI in neurofibromatosis type 1. Pediatr Radiol. 2006;36:1048–56.CrossRefPubMed
6.
go back to reference Griffiths PD, Blaser S, Mukonoweshuro W, Armstrong D, Milo-Mason G, Cheung S. Neurofibromatosis bright objects in children with neurofibromatosis type 1: a proliferative potential? Pediatrics. 1999;104:e49.CrossRefPubMed Griffiths PD, Blaser S, Mukonoweshuro W, Armstrong D, Milo-Mason G, Cheung S. Neurofibromatosis bright objects in children with neurofibromatosis type 1: a proliferative potential? Pediatrics. 1999;104:e49.CrossRefPubMed
7.
go back to reference Menor F, Marti-Bonmati L, Arana E, Poyatos C, Cortina H. Neurofibromatosis type 1 in children: MR imaging and follow-up studies of central nervous system findings. Eur J Radiol. 1998;26:121–31.CrossRefPubMed Menor F, Marti-Bonmati L, Arana E, Poyatos C, Cortina H. Neurofibromatosis type 1 in children: MR imaging and follow-up studies of central nervous system findings. Eur J Radiol. 1998;26:121–31.CrossRefPubMed
8.
go back to reference Park VM, Pivnick EK. Neurofibromatosis type 1 (NF1): a protein truncation assay yielding identification of mutations in 73% of patients. J Med Genet. 1998;35:813–20.CrossRefPubMedPubMedCentral Park VM, Pivnick EK. Neurofibromatosis type 1 (NF1): a protein truncation assay yielding identification of mutations in 73% of patients. J Med Genet. 1998;35:813–20.CrossRefPubMedPubMedCentral
9.
go back to reference Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-East Wales. Brain. 1988;111(Pt 6):1355–81.CrossRefPubMed Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-East Wales. Brain. 1988;111(Pt 6):1355–81.CrossRefPubMed
10.
go back to reference Ostendorf AP, Gutmann DH, Weisenberg JL. Epilepsy in individuals with neurofibromatosis type 1. Epilepsia. 2013;54:1810–4.CrossRefPubMed Ostendorf AP, Gutmann DH, Weisenberg JL. Epilepsy in individuals with neurofibromatosis type 1. Epilepsia. 2013;54:1810–4.CrossRefPubMed
11.
go back to reference Stafstrom CE, Staedtke V, Comi AM. Epilepsy mechanisms in Neurocutaneous disorders: tuberous sclerosis complex, Neurofibromatosis type 1, and Sturge-weber syndrome. Front Neurol. 2017;8:87.CrossRefPubMedPubMedCentral Stafstrom CE, Staedtke V, Comi AM. Epilepsy mechanisms in Neurocutaneous disorders: tuberous sclerosis complex, Neurofibromatosis type 1, and Sturge-weber syndrome. Front Neurol. 2017;8:87.CrossRefPubMedPubMedCentral
12.
go back to reference Hsieh HY, Fung HC, Wang CJ, Chin SC, Wu T. Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects. Seizure. 2011;20:606–11.CrossRefPubMed Hsieh HY, Fung HC, Wang CJ, Chin SC, Wu T. Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects. Seizure. 2011;20:606–11.CrossRefPubMed
13.
go back to reference Pecoraro A, Arehart E, Gallentine W. Epilepsy in neurofibromatosis type 1. Epilepsy Behav. 2017;73:137–41.CrossRefPubMed Pecoraro A, Arehart E, Gallentine W. Epilepsy in neurofibromatosis type 1. Epilepsy Behav. 2017;73:137–41.CrossRefPubMed
14.
15.
go back to reference Vivarelli R, Grosso S, Calabrese F, et al. Epilepsy in neurofibromatosis 1. J Child Neurol. 2003;18:338–42.CrossRefPubMed Vivarelli R, Grosso S, Calabrese F, et al. Epilepsy in neurofibromatosis 1. J Child Neurol. 2003;18:338–42.CrossRefPubMed
16.
go back to reference Miller M, Hall JG. Possible maternal effect on severity of neurofibromatosis. Lancet. 1978;2:1071–3.CrossRefPubMed Miller M, Hall JG. Possible maternal effect on severity of neurofibromatosis. Lancet. 1978;2:1071–3.CrossRefPubMed
17.
go back to reference Riccardi VM, Wald JS. Discounting an adverse maternal effect on severity of neurofibromatosis. Pediatrics. 1987;79:386–93.PubMed Riccardi VM, Wald JS. Discounting an adverse maternal effect on severity of neurofibromatosis. Pediatrics. 1987;79:386–93.PubMed
18.
go back to reference Citraro R, Leo A, Constanti A, Russo E, De Sarro G. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res. 2016;107:333–43.CrossRefPubMed Citraro R, Leo A, Constanti A, Russo E, De Sarro G. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res. 2016;107:333–43.CrossRefPubMed
19.
go back to reference Sadowski K, Kotulska K, Schwartz RA, Jozwiak S. Systemic effects of treatment with mtor inhibitors in tuberous sclerosis complex: a comprehensive review. J Eur Acad Dermatol Venereol. 2016;30:586–94.CrossRefPubMed Sadowski K, Kotulska K, Schwartz RA, Jozwiak S. Systemic effects of treatment with mtor inhibitors in tuberous sclerosis complex: a comprehensive review. J Eur Acad Dermatol Venereol. 2016;30:586–94.CrossRefPubMed
21.
go back to reference Neurofibromatosis. Conference statement. National Institutes of Health consensus development conference. Arch Neurol. 1988;45:575–8. Neurofibromatosis. Conference statement. National Institutes of Health consensus development conference. Arch Neurol. 1988;45:575–8.
22.
go back to reference Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the commission on classification and terminology of the international league against epilepsy. Epilepsia. 1981;22:489–501. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the commission on classification and terminology of the international league against epilepsy. Epilepsia. 1981;22:489–501.
23.
go back to reference American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington: American Psychiatric Association; 1994. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington: American Psychiatric Association; 1994.
24.
go back to reference Korf BR, Carrazana E, Holmes GL. Patterns of seizures observed in association with neurofibromatosis 1. Epilepsia. 1993;34:616–20.CrossRefPubMed Korf BR, Carrazana E, Holmes GL. Patterns of seizures observed in association with neurofibromatosis 1. Epilepsia. 1993;34:616–20.CrossRefPubMed
25.
go back to reference Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475–82.CrossRefPubMed Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475–82.CrossRefPubMed
26.
go back to reference Santoro C, Di Rocco F, Kossorotoff M, Zerah M, Boddaert N, Calmon R, et al. Moyamoya syndrome in children with neurofibromatosis type 1: Italian-French experience. Am J Med Genet A. 2017;173:1521–30.CrossRefPubMed Santoro C, Di Rocco F, Kossorotoff M, Zerah M, Boddaert N, Calmon R, et al. Moyamoya syndrome in children with neurofibromatosis type 1: Italian-French experience. Am J Med Genet A. 2017;173:1521–30.CrossRefPubMed
27.
go back to reference Roth J, Ber R, Wisoff JH, Hidalgo ET, Limbrick DD, Berger DS, et al. Endoscopic third Ventriculostomy in patients with Neurofibromatosis type 1: a multicenter international experience. World Neurosurg. 2017 Nov;107:623–9.CrossRefPubMed Roth J, Ber R, Wisoff JH, Hidalgo ET, Limbrick DD, Berger DS, et al. Endoscopic third Ventriculostomy in patients with Neurofibromatosis type 1: a multicenter international experience. World Neurosurg. 2017 Nov;107:623–9.CrossRefPubMed
28.
go back to reference Santoro C, Maietta A, Giugliano T, Melis D, Perrotta S, Nigro V, et al. Arg(1809) substitution in neurofibromin: further evidence of a genotype-phenotype correlation in neurofibromatosis type 1. Eur J Hum Genet. 2015;23:1460–1.CrossRefPubMedPubMedCentral Santoro C, Maietta A, Giugliano T, Melis D, Perrotta S, Nigro V, et al. Arg(1809) substitution in neurofibromin: further evidence of a genotype-phenotype correlation in neurofibromatosis type 1. Eur J Hum Genet. 2015;23:1460–1.CrossRefPubMedPubMedCentral
29.
go back to reference Jang HM, Park HR, Mun JK, Hwang KJ, Kim J, Hong SC, et al. Surgical treatment of mesial temporal lobe epilepsy in a patient with neurofibromatosis type 1. J Epilepsy Res. 2013;3:35–8.CrossRefPubMedPubMedCentral Jang HM, Park HR, Mun JK, Hwang KJ, Kim J, Hong SC, et al. Surgical treatment of mesial temporal lobe epilepsy in a patient with neurofibromatosis type 1. J Epilepsy Res. 2013;3:35–8.CrossRefPubMedPubMedCentral
30.
go back to reference Barba C, Jacques T, Kahane P, Polster T, Isnard J, Leijten FS, et al. Epilepsy surgery in Neurofibromatosis type 1. Epilepsy Res. 2013;105:384–95.CrossRefPubMed Barba C, Jacques T, Kahane P, Polster T, Isnard J, Leijten FS, et al. Epilepsy surgery in Neurofibromatosis type 1. Epilepsy Res. 2013;105:384–95.CrossRefPubMed
31.
go back to reference Joy P, Roberts C, North K, de Silva M. Neuropsychological function and MRI abnormalities in neurofibromatosis type 1. Dev Med Child Neurol. 1995;37:906–14.CrossRefPubMed Joy P, Roberts C, North K, de Silva M. Neuropsychological function and MRI abnormalities in neurofibromatosis type 1. Dev Med Child Neurol. 1995;37:906–14.CrossRefPubMed
32.
go back to reference Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-Sawatzki H, et al. Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat. 2004;23:111–6.CrossRefPubMed Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-Sawatzki H, et al. Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat. 2004;23:111–6.CrossRefPubMed
33.
go back to reference Van Minkelen R, van Bever Y, Kromosoeto JN, Withagen-Hermans CJ, Nieuwlaat A, Halley DJ, et al. A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands. Clin Genet. 2014;85:318–27.CrossRefPubMed Van Minkelen R, van Bever Y, Kromosoeto JN, Withagen-Hermans CJ, Nieuwlaat A, Halley DJ, et al. A clinical and genetic overview of 18 years neurofibromatosis type 1 molecular diagnostics in the Netherlands. Clin Genet. 2014;85:318–27.CrossRefPubMed
34.
go back to reference Venturin M, Guarnieri P, Natacci F, Stabile M, Tenconi R, Clementi M, et al. Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Med Genet. 2004;41:35–41.CrossRefPubMedPubMedCentral Venturin M, Guarnieri P, Natacci F, Stabile M, Tenconi R, Clementi M, et al. Mental retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Med Genet. 2004;41:35–41.CrossRefPubMedPubMedCentral
35.
go back to reference Miller-Delaney SF, Bryan K, Das S, McKiernan RC, Bray IM, Reynolds JP, et al. Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy. Brain. 2015;138:616–31.CrossRefPubMed Miller-Delaney SF, Bryan K, Das S, McKiernan RC, Bray IM, Reynolds JP, et al. Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy. Brain. 2015;138:616–31.CrossRefPubMed
36.
go back to reference Tan CL, Plotkin JL, Veno MT, von Schimmelmann M, Feinberg P, Mann S, et al. MicroRNA-128 governs neuronal excitability and motor behavior in mice. Science. 2013;342:1254–8.CrossRefPubMedPubMedCentral Tan CL, Plotkin JL, Veno MT, von Schimmelmann M, Feinberg P, Mann S, et al. MicroRNA-128 governs neuronal excitability and motor behavior in mice. Science. 2013;342:1254–8.CrossRefPubMedPubMedCentral
37.
go back to reference Van Eeghen AM, Pulsifer MB, Merker VL, Neumeyer AM, van Eeghen EE, Thibert RL, et al. Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol. 2013;55:146–53.CrossRefPubMed Van Eeghen AM, Pulsifer MB, Merker VL, Neumeyer AM, van Eeghen EE, Thibert RL, et al. Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol. 2013;55:146–53.CrossRefPubMed
38.
go back to reference Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015;17:117–23.PubMed Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015;17:117–23.PubMed
Metadata
Title
Seizures in children with neurofibromatosis type 1: is neurofibromatosis type 1 enough?
Authors
Claudia Santoro
Pia Bernardo
Antonietta Coppola
Umberto Pugliese
Mario Cirillo
Teresa Giugliano
Giulio Piluso
Giuseppe Cinalli
Salvatore Striano
Carmela Bravaccio
Silverio Perrotta
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Italian Journal of Pediatrics / Issue 1/2018
Electronic ISSN: 1824-7288
DOI
https://doi.org/10.1186/s13052-018-0477-x

Other articles of this Issue 1/2018

Italian Journal of Pediatrics 1/2018 Go to the issue